Open Access

Rituximab therapy for lupus nephritis: A meta‑analysis

  • Authors:
    • Lei Shen
    • Xiangying Liu
    • Ci Sun
    • Guoyuan Lu
    • Ling Zhou
    • Jianzhong Li
  • View Affiliations

  • Published online on: July 28, 2021     https://doi.org/10.3892/wasj.2021.119
  • Article Number: 48
  • Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to assess the clinical efficacy and safety of rituximab (RTX) therapy in the treatment of lupus nephritis by performing a meta‑analysis. For this purpose, the PubMed, Embase, Cochrane Library, Chinese Biomedical Literature, China National Knowledge Infrastructure, VIP Information and WANFANG databases were used to identify the eligible studies from January, 2000 to February, 2020. STATA16.0 and Review Manager Version 5.3 software were applied to pool the data. From the results of this search, 37 studies (30 case series and seven controlled trials) involving 1,273 patients were included. In the case series studies, the total remission (TR) rate was 81.9% (95% CI, 73.7‑88.8%) and the complete remission (CR) rate was 46.6% (95% CI, 36.4‑57.1%). Following treatment with RTX, the systemic lupus erythematosus disease activity index (SLEDAI) of patients with lupus nephritis decreased significantly [mean difference (MD), ‑8.91; 95% CI, ‑14.10 to ‑3.72, P<0.01]. The level of proteinuria also decreased significantly [standardized mean difference (SMD), ‑1.05; 95% CI, ‑1.28 to ‑0.83, P<0.01]. On the contrary, the level of serum albumin increased significantly (MD, 6.44; 95% CI, 4.42‑8.45; P<0.01). In the controlled trials, both TR and CR were significantly higher than those of the control group (TR: OR, 2.48; 95% CI, 1.58‑3.89; P<0.01; and CR: OR, 2.29; 95% CI, 1.17‑4.49; P<0.05). Compared with the control group, the SLEDAI of patients in the RTX group decreased significantly (MD, ‑3.84; 95% CI, ‑5.99 to ‑1.69; P<0.01) and the level of proteinuria in the RTX group also decreased significantly (MD, ‑1.24; 95% CI, ‑2.39 to ‑0.09; P<0.05). At the same time, the level of serum albumin increased (MD, 0.54; 95% CI, 0.22‑0.86; P<0.01). There was no difference in the relative risks of the adverse events between the two groups (OR, 0.37; P>0.05). On the whole, the findings of the present study demonstrate that RTX exhibits favorable clinical efficacy in the treatment of lupus nephritis, which can significantly reduce the level of proteinuria and SLEDAI, and increase the level of serum albumin. Compared with traditional immunosuppressive therapy (corticosteroids + cyclophosphamide and/or mycophenolate), RTX was more effective in the treatment of lupus nephritis. Additionally, rituximab exhibited good safety.
View Figures
View References

Related Articles

Journal Cover

September-October 2021
Volume 3 Issue 5

Print ISSN: 2632-2900
Online ISSN:2632-2919

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shen L, Liu X, Sun C, Lu G, Zhou L and Li J: Rituximab therapy for lupus nephritis: A meta‑analysis. World Acad Sci J 3: 48, 2021
APA
Shen, L., Liu, X., Sun, C., Lu, G., Zhou, L., & Li, J. (2021). Rituximab therapy for lupus nephritis: A meta‑analysis. World Academy of Sciences Journal, 3, 48. https://doi.org/10.3892/wasj.2021.119
MLA
Shen, L., Liu, X., Sun, C., Lu, G., Zhou, L., Li, J."Rituximab therapy for lupus nephritis: A meta‑analysis". World Academy of Sciences Journal 3.5 (2021): 48.
Chicago
Shen, L., Liu, X., Sun, C., Lu, G., Zhou, L., Li, J."Rituximab therapy for lupus nephritis: A meta‑analysis". World Academy of Sciences Journal 3, no. 5 (2021): 48. https://doi.org/10.3892/wasj.2021.119